title: Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia.
abstract: Factors that contribute to bone fragility in type 2 diabetes are not well understood. We assessed the effects of intensive glycemic control, thiazolidinediones (TZDs), and A1C levels on bone geometry and strength at the radius and tibia. In a substudy of the Action to Control Cardiovascular Risk in Diabetes trial, peripheral quantitative computed tomographic (pQCT) scans of the radius and tibia were obtained 2 years after randomization on 73 participants (intensive n = 35, standard n = 38). TZD use and A1C levels were measured every 4 months during the trial. Effects of intervention assignment, TZD use, and A1C on pQCT parameters were assessed in linear regression models. Intensive, compared with standard, glycemic control was associated with 1.3 % lower cortical volumetric BMD at the tibia in men (p = 0.02) but not with other pQCT parameters. In women, but not men, each additional year of TZD use was associated with an 11 % lower polar strength strain index (SSIp) at the radius (p = 0.04) and tibia (p = 0.002) in models adjusted for A1C levels. In women, each additional 1 % increase in A1C was associated with an 18 % lower SSIp at the ultradistal radius (p = 0.04) in models adjusted for TZD use. There was no consistent evidence of an effect of intensive, compared with standard, glycemic control on bone strength at the radius or tibia. In women, TZD use may reduce bone strength at these sites. Higher A1C may also be associated with lower bone strength at the radius, but not tibia, in women.
authors: University of California, 185 Berry St., Suite 5700, San Francisco, CA 94107, USA. aschwartz@psg.ucsf.edu
authors: Ann V
authors: AV
authors: Schwartz
authors: Eric
authors: E
authors: Vittinghoff
authors: Karen L
authors: KL
authors: Margolis
authors: Lesley M
authors: LM
authors: Scibora
authors: Lisa
authors: L
authors: Palermo
authors: Walter T
authors: WT
authors: Ambrosius
authors: Trisha F
authors: TF
authors: Hue
authors: Kristine E
authors: KE
authors: Ensrud
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D048909:Diabetes Complications / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011884:Radius / Q000187:drug effects*; D012307:Risk Factors; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013977:Tibia / Q000187:drug effects*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D045162:Thiazolidinediones
references: CMAJ. 2009 Jan 6;180(1):32-9
references: 19073651
references: Diabetes Care. 2010 May;33(5):983-90
references: 20427682
references: Osteoporos Int. 2001;12(9):741-8
references: 11605740
references: J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
references: 16608888
references: J Bone Miner Res. 1997 Feb;12(2):283-9
references: 9041062
references: BMC Endocr Disord. 2011 May 26;11:11
references: 21615901
references: Endocrinology. 2004 Jan;145(1):401-6
references: 14500573
references: Bone. 2008 Apr;42(4):606-15
references: 18280232
references: Diabetes Res Clin Pract. 1994 Feb;23(1):43-54
references: 8013262
references: Arch Intern Med. 2009 Aug 10;169(15):1395-402
references: 19667303
references: Diabetes Obes Metab. 2011 Nov;13(11):1036-46
references: 21682834
references: J Clin Endocrinol Metab. 2008 May;93(5):1696-701
references: 18285411
references: Diabetes Obes Metab. 2010 Aug;12(8):716-21
references: 20590749
references: PLoS Med. 2009 Sep;6(9):e1000154
references: 19787025
references: Diabetes. 2011 Dec;60(12):3271-8
references: 21998400
references: Am J Cardiol. 2007 Jun 18;99(12A):21i-33i
references: 17599422
references: Diabetes Care. 2007 Jun;30(6):1574-6
references: 17363747
references: Osteoporos Int. 2003 Jun;14(4):345-52
references: 12730737
references: J Magn Reson Imaging. 2012 Jan;35(1):117-24
references: 22190287
references: BMC Endocr Disord. 2009 Mar 30;9:10
references: 19331671
references: Diabetes Care. 2012 Jul;35(7):1525-31
references: 22723583
references: Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12
references: 20148906
references: Osteoporos Int. 2007 Jul;18(7):991-7
references: 17268944
references: J Bone Miner Res. 2011 Jan;26(1):63-71
references: 20593412
references: N Engl J Med. 2008 Jun 12;358(24):2545-59
references: 18539917
references: Mol Cell Endocrinol. 2000 Jan 25;159(1-2):7-13
references: 10687847
references: J Clin Endocrinol Metab. 2012 Jan;97(1):234-41
references: 22031520
references: J Cell Biochem. 2007 Dec 15;102(6):1343-57
references: 17975793
references: Osteoporos Int. 2008 Nov;19(11):1549-56
references: 18392664
references: Eur J Epidemiol. 2012 May;27(5):319-32
references: 22451239
references: J Bone Miner Metab. 2010 Sep;28(5):554-60
references: 20177722
references: Diabetologia. 2010 Mar;53(3):489-96
references: 19943156
references: Bone. 1996 Feb;18(2):97-102
references: 8833202
references: Diabetologia. 2012 Nov;55(11):2929-37
references: 22945303
references: J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
references: 17264176
references: Arch Intern Med. 2008 Apr 28;168(8):820-5
references: 18443256
references: Folia Biol (Praha). 2011;57(4):133-8
references: 21978754
references: J Bone Miner Res. 2006 Nov;21(11):1803-10
references: 17002569
references: Osteoporos Int. 2007 Apr;18(4):427-44
references: 17068657